Contract Manufacturers of Sterile Injectables and Non-sterile Products
Jubilant HollisterStier LLC manufactures the following dosage forms in the locations noted:
Jubilant HollisterStier LLC has a well-defined and successful system for transferring products from current facilities to our sites. Products are assigned a Project Manager who is trained and experienced in the complex technical transfer process.
Jubilant HollisterStier LLC is a subsidiary of the Jubilant Pharma Limited.
Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organise our phrama business into three segments. Firstly, 'Specialty Pharmaceuticals' comprising Radiopharmaceuticals (including Radiopharmacies) and Allergy Therapy Products. Secondly, our 'CDMO' segment, comprising Parenteral Contract Manufacturing and Active Pharmaceutical Ingredients. Finally, the 'Generics' segment is for our Finished Dosage Formulations business.
We supply our products and services to customers in over 85 countries. We have four manufacturing facilities in North America and two in India, coupled with Research and Development centers in North America and India. Additionally, we have a distribution network of more than 45 radiopharmacies in the United States.
To find out more about Jubilant Pharma Limited please click here.
Jubilant Pharmova Limited is an integrated global pharmaceuticals company having three business segments Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs.
Jubilant Pharmova Limited has a team of around 6,000 multicultural people across the globe and is committed to delivering value to its customers. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals worldwide.
To find out more about Jubilant Pharmova Limited please click here.
Complete the form below and we will be in touch
We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.